Founded in 2010, Neuromod Devices is a global medical technology business with 136 worldwide patents. Neuromod has offices in Ireland, Germany and the US. Neuromod’s tinnitus technology, Lenire, is the first tinnitus treatment device of its kind approved by the US FDA following a third large-scale clinical trial.
Neuromod Device’s Mission
Neuromod’s mission is to research and develop innovative technologies to address the clinical needs of underserved patient populations living with complex and debilitating neurological conditions. We achieve this through commitment to evidence based solutions, industry collaboration and community engagement.
Founding Neuromod Devices
Dr. Ross O’Neill became interested in tinnitus during his Biomedical Engineering PhD. Speaking with those who were profoundly effected by tinnitus piqued his interest.
Dr. O’Neill became alarmed at the limited treatment options available for a condition that affects 10 – 15% of the global population. Tinnitus patients were trapped on a referral carousel from family doctor to ENT to audiologist and back again. Change was needed.
Dr. O’Neill’s PhD investigated auditory and somatic system interaction. The aim was to discover how neuromodulation could treat tinnitus. After his PhD, Dr. O’Neill formed Neuromod Devices to develop Lenire.
What is Lenire?
Lenire is the first and only bimodal neuromodulation (dual mode) tinnitus treatment technology awarded a De Novo Grant by the US FDA. Extensive clinical trial results show Lenire to be safe and effective at treating tinnitus.^
Neuromod Device’s management includes neuroscientists, ENTs, audiologists, clinicians, regulatory experts, product designers and more. We share a commitment towards achieving breakthroughs for underserved patients. Together, we bridge the gap between research, industry and clinical practice to offer patients a better quality of life.
Dr. Ross O’Neill PhD MBA Founder & CEO
Mr. Brendan Conlon PhD Chief Medical Officer
Dr. Hubert Lim PhD Chief Scientific Officer
Florian Elsaesser Chief Strategy & Corporate Development Officer
Diarmuid Flavin Chief Operating Officer
Derek Madden CPA CTax Chief Financial Officer
Caroline Hamilton BSc (Aud), MSc (Neuro) Clinical Director
Eric Timm President, Global Commercial Operations & Chief Executive Officer, Neuromod USA
Dr. Tish Ramirez Chief Commercial Officer, Neuromod USA
Stephanie Glowacki Chief Financial Officer, Neuromod USA
Find a Clinic Near You
Lenire has expert Partner Clinics across America, Europe, and the United Kingdom. Use the Lenire Clinic Map to start your treatment with Lenire.
1. TENT-A1 Conlon et al., Sci. Transl. Med. 12, eabb2830 (2020) 2. TENT-A2: Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep. 3. TENT-A3: Clinical trial data in preparation for independent publication: clinicaltrials.gov/ct2/show/NCT05227365. 4. Aggregate: TENT-A1, TENT-A2, TENT-A3 aggregate clinical trial results.
Note 1: All statistics based on compliant patients. Patient compliance criteria is detailed in Lenire’s clinical trial design. Note 2: TENT-A1/TENT-A2 were not considered by the United States of America FDA as part of Lenire’s FDA Grant and, as such, applies solely to outside the US.